Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Roman HájekJiří MinaříkJan StraubLuděk PourAlexandra JungovaJesus G BerdejaMario BoccadoroLucie BrozovaAndrew SpencerFrits van RheeJorge Vela-OjedaMichael A ThompsonRafat AbonourAjai ChariGordon CookCaitlin L CostelloFaith E DaviesVania Tm HungriaHans C LeeXavier LeleuNoemi PuigRobert M RifkinEvangelos TerposSaad Z UsmaniKatja C WeiselJeffrey A ZonderMagda BařinováMatyáš KuhnJiří ŠilarLenka ČápkováKenny GalvezJin LuJennifer ElliottDawn Marie StullKaili RenVladimír MaisnarPublished in: Future oncology (London, England) (2021)
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).
Keyphrases
- multiple myeloma
- newly diagnosed
- clinical practice
- end stage renal disease
- clinical trial
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- systematic review
- stem cells
- stem cell transplantation
- acute myeloid leukemia
- acute lymphoblastic leukemia
- mesenchymal stem cells
- bone marrow
- artificial intelligence
- smoking cessation